Publication Date
In 2025 | 0 |
Since 2024 | 0 |
Since 2021 (last 5 years) | 0 |
Since 2016 (last 10 years) | 1 |
Since 2006 (last 20 years) | 3 |
Descriptor
Antisocial Behavior | 3 |
Autism | 3 |
Pervasive Developmental… | 3 |
Symptoms (Individual… | 3 |
Behavior Problems | 2 |
Check Lists | 2 |
Children | 2 |
Drug Therapy | 2 |
Adolescents | 1 |
Aggression | 1 |
Behavior Modification | 1 |
More ▼ |
Source
Journal of Autism and… | 3 |
Author
Publication Type
Journal Articles | 3 |
Reports - Research | 3 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
Aberrant Behavior Checklist | 3 |
What Works Clearinghouse Rating
Hirota, Tomoya; Deserno, Marie; McElroy, Eoin – Journal of Autism and Developmental Disorders, 2020
Irritability and aggression (IA) are highly prevalent in individuals with autism spectrum disorder (ASD). Although clinical correlates of IA in this population have been previously examined, findings from existing studies capturing symptoms as a set of latent variables do not fully explain meaningful associations between the symptoms themselves.…
Descriptors: Aggression, Antisocial Behavior, Autism, Pervasive Developmental Disorders
Erickson, Craig A.; Wink, Logan K.; Early, Maureen C.; Stiegelmeyer, Elizabeth; Mathieu-Frasier, Lauren; Patrick, Vanessa; McDougle, Christopher J. – Journal of Autism and Developmental Disorders, 2014
Rationale: An excitatory/inhibitory (E:I) imbalance marked by enhanced glutamate and deficient gamma-aminobutyric acid (GABA) neurotransmission may contribute to the pathophysiology of autism spectrum disorders (ASD). Objectives: We report on the first single-blind placebo lead-in trial of acamprosate, a drug with putative mechanisms restoring E:I…
Descriptors: Autism, Pervasive Developmental Disorders, Drug Therapy, Metabolism
Pandina, Gahan J.; Bossie, Cynthia A.; Youssef, Eriene; Zhu, Young; Dunbar, Fiona – Journal of Autism and Developmental Disorders, 2007
Subgroup analysis of children (5-12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders. The primary efficacy measure was the Aberrant Behavior Checklist-Irritability (ABC-I) subscale. Data were available for 55 children given risperidone (n = 27) or placebo (n =…
Descriptors: Autism, Drug Therapy, Children, Behavior Modification